Document Detail

Intervention to reduce unnecessary dispensing of short-acting {beta}-agonists in patients with asthma.
MedLine Citation:
PMID:  20233916     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Several clinical studies have suggested that the overuse of short-acting beta-agonists (SABAs) and the underuse of inhaled corticosteroids are prevalent and may compromise patient health and increase the use of scarce health-care resources. OBJECTIVE: To examine the impact of an intervention designed to reduce SABA metered-dose inhaler (MDI) overdispensing on asthma-related drug and healthcare utilization endpoints in a mail order pharmacy benefit population. METHODS: Retrospective pre- and postintervention analysis was conducted on all new SABA prescriptions indicating a quantity more than 1 SABA MDI per month and on asthma patients who were continuously enrolled in the Medco Health Solutions prescription benefit program from July 1, 2006, to June, 30, 2007 (preintervention), and July 1, 2007, to June 30, 2008 (postintervention). The intervention involved a written or verbal request to the prescriber to reduce the quantity of SABA MDIs dispensed to less than 1 SABA MDI per month if determined appropriate by the prescriber. Effectiveness of the intervention on asthma-related drug and health-care utilization outcomes were measured in the overall Medco pharmacy population and in asthma patients receiving more than 1 SABA MDI per month. RESULTS: The percentage of new SABA prescriptions dispensed for more than 1 SABA MDI per month was significantly reduced during year 2 (22.9% vs 9.7%, p < 0.01). Of the 1835 asthma patients who received more than 1 SABA MDI per month in year 1, 1230 (67%) received fewer than 1 SABA MDI per month during year 2. The incidence of asthma-related hospitalizations, emergency department visits, and oral corticosteroid use did not significantly change from year 1 to year 2. CONCLUSIONS: This analysis shows that an intervention can succeed in reducing the overdispensing of quick-relief medication without compromising asthma control. Further investigation is warranted to better understand the interplay between reduction in excessive SABA use and improved clinical outcomes.
Mark D Wong; R Thomas Manley; Glen Stettin; William Chen; Luis M Salmun
Related Documents :
10805356 - Intravenous immunoglobulin treatment of lupus nephritis.
2105676 - Continuous intravenous terbutaline infusions for adult patients with status asthmaticus.
8508556 - Prednisone and piroxicam for treatment of primary sjögren's syndrome.
10331506 - Chronic pure red cell aplasia caused by parvovirus b19 in aids: use of intravenous immu...
14622636 - The effect of early education on patient anxiety while waiting for elective cardiac cat...
18325216 - Thorascopic sympathectomy performed using laser.
Publication Detail:
Type:  Journal Article     Date:  2010-03-16
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-25     Completed Date:  2010-06-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  623-9     Citation Subset:  IM    
Pulmonary Therapeutic Resource Center, Medco Health Solutions, Inc., Liberty Lake, WA 99019, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / adverse effects,  economics,  therapeutic use
Adrenergic beta-Agonists / adverse effects*,  economics,  therapeutic use
Asthma / drug therapy*,  economics
Cohort Studies
Cost Savings
Databases, Factual
Drug Prescriptions / statistics & numerical data
Drug Utilization
Logistic Models
Middle Aged
Patient Education as Topic*
Retrospective Studies
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Adrenergic beta-Agonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of Inhaled Corticosteroids in Monotherapy or Combined with Long-Acting {beta}2-Agonists on M...
Next Document:  Toxicities of gemcitabine in patients with severe hepatic dysfunction.